These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 39097194)
1. Engineered bacteria breach tumor physical barriers to enhance radio-immunotherapy. Zhang Y; Liu Y; Li T; Yang X; Lang S; Pei P; Pei H; Chang L; Hu L; Liu T; Yang K J Control Release; 2024 Sep; 373():867-878. PubMed ID: 39097194 [TBL] [Abstract][Full Text] [Related]
2. Nattokinase-Mediated Regulation of Tumor Physical Microenvironment to Enhance Chemotherapy, Radiotherapy, and CAR-T Therapy of Solid Tumor. Zhang Y; Pei P; Zhou H; Xie Y; Yang S; Shen W; Hu L; Zhang Y; Liu T; Yang K ACS Nano; 2023 Apr; 17(8):7475-7486. PubMed ID: 37057972 [TBL] [Abstract][Full Text] [Related]
4. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer. Ding D; Liang R; Li T; Lan T; Li Y; Huang S; He G; Ren J; Li W; Zheng Z; Chen T; Fang J; Huang L; Shuai X; Wei B J Control Release; 2024 May; 369():309-324. PubMed ID: 38554771 [TBL] [Abstract][Full Text] [Related]
5. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. Fu C; Jiang A Front Immunol; 2018; 9():3059. PubMed ID: 30619378 [TBL] [Abstract][Full Text] [Related]
6. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
7. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Chen M; Xiang R; Wen Y; Xu G; Wang C; Luo S; Yin T; Wei X; Shao B; Liu N; Guo F; Li M; Zhang S; Li M; Ren K; Wang Y; Wei Y Sci Rep; 2015 Sep; 5():14421. PubMed ID: 26394925 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846 [No Abstract] [Full Text] [Related]
10. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors. Wang H; Najibi AJ; Sobral MC; Seo BR; Lee JY; Wu D; Li AW; Verbeke CS; Mooney DJ Nat Commun; 2020 Nov; 11(1):5696. PubMed ID: 33173046 [TBL] [Abstract][Full Text] [Related]
11. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo. Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377 [TBL] [Abstract][Full Text] [Related]
12. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor. Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858 [No Abstract] [Full Text] [Related]
13. Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable. Fabian KP; Malamas AS; Padget MR; Solocinski K; Wolfson B; Fujii R; Abdul Sater H; Schlom J; Hodge JW Cancer Immunol Res; 2021 Feb; 9(2):239-252. PubMed ID: 33355290 [TBL] [Abstract][Full Text] [Related]
14. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976 [TBL] [Abstract][Full Text] [Related]
15. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935 [TBL] [Abstract][Full Text] [Related]
16. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. Wang D; Jiang W; Zhu F; Mao X; Agrawal S Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749 [TBL] [Abstract][Full Text] [Related]
17. IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration. Yang W; Chen Z; Qu L; Zhang C; Chen H; Zheng J; Chen W; Tan X; Shi C Curr Cancer Drug Targets; 2024; 24(6):642-653. PubMed ID: 38310462 [TBL] [Abstract][Full Text] [Related]
18. Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens. Yin M; Liu Z; Zhou Y; Li W; Yan J; Cao D; Yin L J Control Release; 2024 Sep; 373():358-369. PubMed ID: 39009083 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056 [TBL] [Abstract][Full Text] [Related]
20. Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy. Rossowska J; Anger N; Szczygieł A; Mierzejewska J; Pajtasz-Piasecka E J Exp Clin Cancer Res; 2018 Jun; 37(1):126. PubMed ID: 29954431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]